The 145th Annual Meeting of the Pharmaceutical Society of Japan (Fukuoka)

Organizer: Shinya Ohata (Facul. Pharm., Musashino Univ.), Sachiko Toma (NAIST)

In Japan, cancer represents the primary cause of mortality, accounting for over a quarter of all deaths. Despite the advent of numerous therapeutic agents and pharmaceuticals, these have yet to be validated for the treatment of rare and refractory cancers, leaving significant unmet medical needs. As evidenced by the pivotal role played by structural biology in the development of imatinib, it is anticipated that collaboration among experts in disparate fields will yield novel ideas and approaches that will culminate in transformative outcomes. The symposium will present the works of leading researchers in the field of cancer research. This will include the development of in vivo model systems, the discovery of new drug targets, and the development of drugs using an integrated approach that combines biological methods with structural biology, synthetic organic chemistry, radiochemistry, computer science, developmental engineering, and other techniques. The research of these frontrunners will be introduced, and the importance of interdisciplinary collaboration in the development of diagnostic and therapeutic methods for cancer and other diseases will be discussed.